<DOC>
	<DOCNO>NCT02372097</DOCNO>
	<brief_summary>The purpose study investigate bioequivalence 2 tablet SYR-472 25 milligram ( mg ) 1 tablet SYR-472 50 mg administer healthy adult male .</brief_summary>
	<brief_title>A Phase 1 , Bioequivalence Study SYR-472 25mg 50mg Tablets</brief_title>
	<detailed_description>Bioequivalence 2 SYR-472 25 mg tablet 1 SYR-472 50 mg tablet administer healthy adult male investigate randomized , open-label , crossover study .</detailed_description>
	<criteria>1 . Participants understand outline clinical study capable comply responsibility participant , judge investigator sub investigator . 2 . Participants sign date inform consent form initiation study procedure . 3 . Healthy Japanese adult male . 4 . Participants 20 35 year age time informed consent . 5 . Participants weigh 50.0 kilogram ( kg ) body mass index ( BMI ) 18.5 less 25.0 kilogram per square meter ( kg/m^2 ) screening period . 1 . Participants administer investigational product within 16 week ( 112 day ) start study drug administration stage 1 . 2 . Participants receive SYR472 past . 3 . Employees study site , family member , dependency relationship employee study site involve conduct study ( example [ e.g . ] , spouse , parent , child , brother sister ) , might coerce consent participate study . 4 . Participants poorly control , clinically significant abnormality nervous system , cardiovascular system , lung , liver , kidney , metabolism , gastrointestinal system , urinary system , endocrinological system , possibly may affect study participation study result . 5 . Participants positive urine drug test screening period . 6 . Participants need use drug food list table prohibit concomitant drug food . 7 . Participants history hypersensitivity allergy drug ( include SYR472 ingredient ) . 8 . Participants currently recently ( within past 6 month ) gastrointestinal disease may affect drug absorption ( malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ least week ] heartburn , surgical intervention [ e.g. , cholecystectomy ] ) . 9 . Participants past history cancer . 10 . Participants positive follow screening period : hepatitis B virus surface antigen ( HBsAg ) , antibody hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) antigen , antiHIV antibody , serological test syphilis . 11 . Participants difficulty blood collect peripheral vein . 12 . Participants donate 200 milliliter ( mL ) whole blood within 4 week ( 28 day ) 400 mL whole blood within 12 week ( 84 day ) start study drug administration stage 1 . 13 . Participants donate total 800 mL whole blood within 52 week ( 364 day ) start study drug administration stage 1 . 14 . Participants donate blood component within 2 week ( 14 day ) start study drug administration stage 1 . 15 . Participants show clinically significant abnormality electrocardiogram ( ECG ) screen period Day 1 ( study drug administration ) . 16 . Participants laboratory test abnormality suggestive clinically significant primary disease abnormal value follow parameter : alanine aminotransferase ( ALT ) aspartate serum transaminase AST exceed 1.5 time upper limit normal range . 17 . Participants unlikely comply study protocol ineligible study reason , judge investigator sub investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>